AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3297718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29077226 — intervention group
Group type: EXPERIMENTAL
Intervention: Shark fin trade assessment using genetic identification of fin trimmings
Number of subjects: 4800
Study 29077226 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian model for species composition
Number of subjects: 4800
Study 29077226 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of management measures
Number of subjects: 4800
Study 26833744 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 4372
Study 25556490 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine combined with oxycodone prolonged-release tablets
Number of subjects: 120
Study 25556490 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone prolonged-release tablets alone (Control)
Number of subjects: 120
Study 22250667 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message for potential fakers in Study 1
Number of subjects: 543
Study 22250667 — intervention group
Group type: COMPARATOR
Intervention: Nonwarning (control) message for nonfakers in Study 1
Number of subjects: 543
Study 22250667 — intervention group
Group type: EXPERIMENTAL
Intervention: Warning message in Study 2
Number of subjects: 543
Study 22250667 — intervention group
Group type: COMPARATOR
Intervention: Control message in Study 2
Number of subjects: 543
Study 19765784 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude (ALT, 4300 m)
Number of subjects: 8
Study 19765784 — intervention group
Group type: COMPARATOR
Intervention: Ambient conditions (AMB, 362 m)
Number of subjects: 8
Study 17884832 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose paediatric granule co-formulation (10-20 kg body weight)
Number of subjects: 24
Study 17884832 — intervention group
Group type: COMPARATOR
Intervention: Free-dose co-blister tablet formulation of artesunate-mefloquine (>20-40 kg body weight)
Number of subjects: 24
Study 15722369 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 93
Study 15722369 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 93
Study 15722369 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 12148181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollinex
Number of subjects: 27
Study 12148181 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergovit
Number of subjects: 27
Study 12148181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pollinex or Allergovit
Number of subjects: 27
Study 9296767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 levels
Number of subjects: 0
Study 9296767 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyfra 21-1 concentration
Number of subjects: 0
Study 9296767 — intervention group
Group type: EXPERIMENTAL
Intervention: High Cyfra 21 levels
Number of subjects: 0
Study 3353893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3.2 g eicosapentaenoic acid and 2.2 g docosahexaenoic acid daily)
Number of subjects: 20
Study 3353893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 20
Study 31227535 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral probiotic combination of Lactobacillus rhamnosus, GG (LGG) and Bifidobacterium animalis subsp. lactis, BB‐12 (BB‐12)
Number of subjects: 330
Study 31227535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 28463747 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-SP (Cognitive Behaviour Therapy with Support Person)
Number of subjects: 201
Study 28463747 — intervention group
Group type: COMPARATOR
Intervention: CBT-A (Cognitive Behaviour Therapy Alone)
Number of subjects: 201
Study 24602689 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise group (150 additional minutes of exercise per week)
Number of subjects: 129
Study 24602689 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive exercise group (300 additional minutes of exercise per week)
Number of subjects: 129
Study 24602689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 129
Study 23015541 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (65 mg)
Number of subjects: 128
Study 23015541 — intervention group
Group type: COMPARATOR
Intervention: De-caffeinated coffee
Number of subjects: 128
Study 21464363 — intervention group
Group type: EXPERIMENTAL
Intervention: High alcohol dose (0.8 g/kg)
Number of subjects: 190
Study 21464363 — intervention group
Group type: EXPERIMENTAL
Intervention: Low alcohol dose (0.4 g/kg)
Number of subjects: 190
Study 21464363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 21464363 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy drinkers
Number of subjects: 190
Study 21464363 — intervention group
Group type: EXPERIMENTAL
Intervention: Binge drinking frequency during follow‐up
Number of subjects: 190
Study 19394989 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria education
Number of subjects: 213
Study 17091055 — intervention group
Group type: EXPERIMENTAL
Intervention: Coca tea consumption
Number of subjects: 5
Study 14969023 — intervention group
Group type: EXPERIMENTAL
Intervention: Profore (four-layer bandage system)
Number of subjects: 68
Study 14969023 — intervention group
Group type: COMPARATOR
Intervention: Unna's Boot
Number of subjects: 68
Study 14969023 — intervention group
Group type: EXPERIMENTAL
Intervention: Profore
Number of subjects: 68
Study 11817382 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in a therapeutic trial
Number of subjects: 43
Study 9457454 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracaine 1%
Number of subjects: 38
Study 9457454 — intervention group
Group type: COMPARATOR
Intervention: Topical bupivacaine 0.75%
Number of subjects: 38
Study 7649759 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive community intervention
Number of subjects: 0
Study 7649759 — intervention group
Group type: COMPARATOR
Intervention: Control group (adolescents who did not experience peer suicide)
Number of subjects: 0
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine 20, 30 or 40 mg/kg
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 20, 30 or 40 mg/kg
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 30 or 40 mg/kg
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine 40 mg/kg
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dosages of both drugs
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Cured adults in Bulamata
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults in Bulinga and Maramvya
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Population chemotherapy
Number of subjects: 1320
Study 2514474 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower treatment schedules
Number of subjects: 1320
Study 1055315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine alone or in conjunction with diuretics and other hypertensive drugs
Number of subjects: 50
Study 1055315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50
Study 31314549 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive surveillance strategies
Number of subjects: 35200
Study 31314549 — intervention group
Group type: COMPARATOR
Intervention: Less intensive surveillance strategies
Number of subjects: 35200
Study 28682969 — intervention group
Group type: EXPERIMENTAL
Intervention: Early colonoscopy (<30 days from referral)
Number of subjects: 257
Study 28682969 — intervention group
Group type: COMPARATOR
Intervention: Standard-schedule colonoscopy
Number of subjects: 257
Study 24663814 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol chewing gum (6 g/day for 5 weeks)
Number of subjects: 73
Study 24663814 — intervention group
Group type: COMPARATOR
Intervention: Sorbitol chewing gum (control group)
Number of subjects: 73
Study 23158806 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200-15 Agile Patch (AP) under normal conditions
Number of subjects: 24
Study 23158806 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200-15 Agile Patch (AP) under cool water conditions
Number of subjects: 24
Study 23158806 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200-15 Agile Patch (AP) under all conditions
Number of subjects: 24
Study 22285289 — intervention group
Group type: COMPARATOR
Intervention: Placebo effects
Number of subjects: 12
Study 22285289 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 12
Study 22285289 — intervention group
Group type: COMPARATOR
Intervention: Psychological mechanisms
Number of subjects: 12
Study 22285289 — intervention group
Group type: COMPARATOR
Intervention: Holistic models of healing
Number of subjects: 12
Study 22285289 — intervention group
Group type: COMPARATOR
Intervention: Negative views of placebos
Number of subjects: 12
Study 19616494 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at 10 weeks of age
Number of subjects: 46
Study 19616494 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at birth
Number of subjects: 46
Study 17900512 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic propyl gallate (CPG)
Number of subjects: 116
Study 17900512 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine diphosphate (ADP)
Number of subjects: 116
Study 17900512 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CPG and ADP
Number of subjects: 116
Study 17900512 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 116
Study 14991243 — intervention group
Group type: EXPERIMENTAL
Intervention: [(18)F]fluorothymidine (FLT) PET
Number of subjects: 12
Study 11254838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous pressure (PVP) during surgery
Number of subjects: 150
Study 11254838 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral venous pressure (PVP) in the postanesthesia care unit
Number of subjects: 150
Study 11254838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid challenge (2-L) in intraoperative patients
Number of subjects: 150
Study 9479686 — intervention group
Group type: EXPERIMENTAL
Intervention: Civilian version of the Mississippi Scale for Combat‐Related PTSD (CM‐PTSD)
Number of subjects: 52
Study 9479686 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma Symptom Checklist‐40 (TSC‐40)
Number of subjects: 52
Study 9479686 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to Childhood Incest Questionnaire (RCIQ)
Number of subjects: 52
Study 7913934 — intervention group
Group type: EXPERIMENTAL
Intervention: RAI alone
Number of subjects: 114
Study 7913934 — intervention group
Group type: COMPARATOR
Intervention: Adjunctive antithyroid drugs (MMI and L-T4)
Number of subjects: 114
Study 7913934 — intervention group
Group type: COMPARATOR
Intervention: Both groups (RAI and adjunctive antithyroid drugs)
Number of subjects: 114
Study 7913934 — intervention group
Group type: EXPERIMENTAL
Intervention: MMI
Number of subjects: 114
Study 7913934 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with hypothyroidism and elevated TSH
Number of subjects: 114
Study 7913934 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with no ophthalmopathy at presentation
Number of subjects: 114
Study 7913934 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed or had exacerbation of GO
Number of subjects: 114
Study 2847600 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg nedocromil sodium
Number of subjects: 12
Study 2847600 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nedocromil sodium
Number of subjects: 12
Study 2847600 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg nedocromil sodium
Number of subjects: 12
Study 2847600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30471715 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3 (250 µg/kg/24 hours, continuous intravenous infusion from <24 hours of birth to postmenstrual age 296/7 weeks)
Number of subjects: 121
Study 30471715 — intervention group
Group type: COMPARATOR
Intervention: Standard neonatal care
Number of subjects: 121
Study 30471715 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Number of subjects: 121
Study 30471715 — intervention group
Group type: COMPARATOR
Intervention: rhIGF-1/rhIGFBP-3 and Standard neonatal care
Number of subjects: 121
Study 27505045 — intervention group
Group type: EXPERIMENTAL
Intervention: Early flap coverage (≤3 weeks)
Number of subjects: 55
Study 27505045 — intervention group
Group type: COMPARATOR
Intervention: Late flap coverage (>3 weeks)
Number of subjects: 55
Study 25196399 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based dispensing of hormonal contraceptives by nurses
Number of subjects: 24
Study 23744766 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 9
Study 22142523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency treatment
Number of subjects: 30
Study 22142523 — intervention group
Group type: COMPARATOR
Intervention: Greater occipital nerve block with steroid
Number of subjects: 30
Study 19737849 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor prescribed to be taken as needed for relief of epigastric pain
Number of subjects: 0
Study 19737849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16490093 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal morphine (30 microg.kg(‐1) in 1 ml.kg(‐1) saline)
Number of subjects: 28
Study 16490093 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine (0.25%)
Number of subjects: 28
Study 14642016 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine
Number of subjects: 8
Study 14642016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 11345025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ukrain (10 mg every second day, repeated 10 times) and vitamin C (5.4 g every second day, repeated 10 times)
Number of subjects: 42
Study 11345025 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin C (5.4 g every second day, repeated 10 times) and normal saline (10 ml))
Number of subjects: 42
Study 9192511 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate (400 mg/day for 14 days) followed by cyclical calcitriol therapy (0.25 microg twice daily)
Number of subjects: 30
Study 9192511 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg twice daily)
Number of subjects: 30
Study 9192511 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg/day) in combination with 100 IU intranasal salmon calcitonin every other day
Number of subjects: 30
Study 1492900 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable infra-red CO2 detector
Number of subjects: 50
Study 3515920 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (200 to 300 mg total daily dosage, four times daily)
Number of subjects: 68
Study 3515920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 31860408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 365
Study 31860408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study 29962548 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (educational sessions with male partners)
Number of subjects: 1144
Study 29962548 — intervention group
Group type: COMPARATOR
Intervention: Control arm (routine care only)
Number of subjects: 1144
Study 27261984 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga program for 12 weeks
Number of subjects: 335
Study 27261984 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise-training program for 12 weeks
Number of subjects: 335
Study 27261984 — intervention group
Group type: COMPARATOR
Intervention: Usual activity group
Number of subjects: 335
Study 24218048 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 30
Study 24218048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22682100 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR self-monitoring system
Number of subjects: 87
Study 20140408 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (18 sessions including manual mobilization, taping and exercises, n = 29)
Number of subjects: 48
Study 20140408 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation (n = 15 compliant patients)
Number of subjects: 48
Study 20140408 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 48
Study 20140408 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-list, n = 19)
Number of subjects: 48
Study 17239139 — intervention group
Group type: EXPERIMENTAL
Intervention: True bipolar configuration (Medtronic Sprint Quattro)
Number of subjects: 40
Study 17239139 — intervention group
Group type: EXPERIMENTAL
Intervention: True bipolar configuration (St. Jude Riata)
Number of subjects: 40
Study 17239139 — intervention group
Group type: COMPARATOR
Intervention: Integrated bipolar configuration (Medtronic Sprint Quattro)
Number of subjects: 40
Study 17239139 — intervention group
Group type: COMPARATOR
Intervention: Integrated bipolar configuration (St. Jude Riata)
Number of subjects: 40
Study 17239139 — intervention group
Group type: EXPERIMENTAL
Intervention: True bipolar configuration
Number of subjects: 40
Study 17239139 — intervention group
Group type: COMPARATOR
Intervention: Integrated bipolar configuration
Number of subjects: 40
Study 15231982 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-Daily Dosing (ODD) of aminoglycosides
Number of subjects: 1949
Study 15231982 — intervention group
Group type: COMPARATOR
Intervention: Multiple Daily Dosing (MDD) of aminoglycosides
Number of subjects: 1949
Study 11752995 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-assisted learning
Number of subjects: 144
Study 11752995 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted learning
Number of subjects: 144
Study 9578507 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily s.c. injections of 0.9 mg/m2 hGH
Number of subjects: 34
Study 9578507 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 34
Study 7715582 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant treatment with selenium
Number of subjects: 0
Study 7715582 — intervention group
Group type: EXPERIMENTAL
Intervention: Scavenger treatment
Number of subjects: 0
Study 2116042 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 77
Study 2116042 — intervention group
Group type: COMPARATOR
Intervention: GST
Number of subjects: 77
Study 619607 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenylhydantoin (DPH) at a concentration of 20 microgram/ml
Number of subjects: 11
Study 619607 — intervention group
Group type: COMPARATOR
Intervention: Control solution of orange juice
Number of subjects: 11
Study 30701613 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (380 mg intramuscularly injected every four weeks)
Number of subjects: 143
Study 30701613 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone (flexible 4-16 mg sublingual doses daily)
Number of subjects: 143
Study 30701613 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from buprenorphine-naloxone to extended-release naltrexone
Number of subjects: 143
Study 30701613 — intervention group
Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 143
Study 28302527 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple plastic stents (MPSs)
Number of subjects: 58
Study 28302527 — intervention group
Group type: COMPARATOR
Intervention: Covered self-expandable metal stents (cSEMSs)
Number of subjects: 58
Study 28302527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 26471464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexident Post (BP) gel, used three times daily after tooth extraction.
Number of subjects: 47
Study 26471464 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate (BC) oral rinse, used three times daily after tooth extraction.
Number of subjects: 47
Study 22733001 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild blueberry drink (25 g freeze-dried powder providing 375 mg of ACNs)
Number of subjects: 18
Study 22733001 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink
Number of subjects: 18
Study 20832955 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 33
Study 19923636 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclectin
Number of subjects: 18
Study 19923636 — intervention group
Group type: COMPARATOR
Intervention: Oral solutions of doxylamine succinate and pyridoxine hydrochloride
Number of subjects: 18
Study 15860696 — intervention group
Group type: EXPERIMENTAL
Intervention: IV corticosteroids
Number of subjects: 1847
Study 15860696 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids
Number of subjects: 1847
Study 11807721 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 0
Study 11807721 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone
Number of subjects: 0
Study 11807721 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a single DHFR mutation (Arg-59) with a single DHPS mutation (Glu-540)
Number of subjects: 0
Study 10628575 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Education Program (2 4-hour interactive workshops)
Number of subjects: 49
Study 10628575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 49
Study 7549079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue plasminogen activator
Number of subjects: 0
Study 7549079 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous heparin
Number of subjects: 0
Study 7549079 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, beta-blockers, converting enzyme inhibitors
Number of subjects: 0
Study 7549079 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates and magnesium
Number of subjects: 0